Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 3.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 1.8 | - |
NAV | ₹518.88 | - |
Fund Started | 10 May 2004 | - |
Fund Size | ₹8357.03 Cr | - |
Exit Load | Exit load of 1% if redeemed within 1 month. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -1.63% | - |
3 Year | 22.87% | - |
5 Year | 19.06% | - |
1 Year
3 Year
5 Year
Equity | 99.46% | - |
Cash | 0.54% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.94% |
Divi's Laboratories Ltd. | 7.34% |
Cipla Ltd. | 6.09% |
Lupin Ltd. | 6.09% |
Apollo Hospitals Enterprise Ltd. | 5.91% |
Dr. Reddy's Laboratories Ltd. | 5.90% |
Medplus Health Services Ltd. | 3.65% |
Vijaya Diagnostic Centre Ltd. | 3.48% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.04% |
Gland Pharma Ltd. | 2.96% |
Name | Akshay Sharma | - |
Start Date | 01 Dec 2022 | - |
Name
Start Date
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | - |
Launch Date | 10 May 2004 | - |
Description
Launch Date